drugset / Trial / NCT00841854
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication
Phase 4
Completed
199 enrolled
Asan Medical Center
Inje University · collabPacific Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
At present, triple therapy are recommended by various guidelines for the treatment of Helicobacter pylori (H. pylori) infection. Recent studies have shown worldwide high treatment failure rates with one week first line clarithromycin based triple therapy necessitating salvage strategy to eradicate H. pylori in primary treatment failure. However, the exact duration of bismuth based second line treatment is not determined. Therefore, the investigators performed this study to evaluate the eradication rate of 1 or 2-week quadruple regimen as a second-line therapy.
Timeline
- Start
- 2008-06
- Primary completion
- 2010-05
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bismuth Potassium Citrate | Unknown | 300 mg | — |
| Comparator | Metronidazole | Small molecule | 500 mg | — |
| Comparator | Pantoprazole | Other / unclassified | 40 mg | — |
| Comparator | Tetracycline | Unknown | 500 mg | — |